Drug intelligence / Profile preview

paracetamol + orphenadrine (The Searle Company)

Development stage
Unknown
Lead developer
The Searle Company
Modality
Small Molecules
Administration
Oral
01

Overview

Nuberol Forte is a fixed-dose combination of paracetamol (acetaminophen) and orphenadrine citrate, primarily used as an analgesic and skeletal muscle relaxant. Paracetamol provides antipyretic and analgesic effects, likely through the inhibition of cyclooxygenase enzymes and subsequent reduction in prostaglandin synthesis within the central nervous system. Orphenadrine acts as a centrally acting muscle relaxant, exhibiting anticholinergic and antihistaminic properties; its muscle relaxant effects are attributed to its activity in the brain stem, where it antagonizes NMDA receptors. This combination is frequently prescribed for the symptomatic relief of painful musculoskeletal conditions, including chronic neck pain, low back pain, and muscle spasms. It is manufactured and marketed by The Searle Company, particularly in the Pakistani pharmaceutical market.

Brand names
Nuberol ForteNuberol
Other names
acetaminophen + orphenadrine
02

Targets

HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on paracetamol + orphenadrine (The Searle Company).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + orphenadrine (The Searle Company).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call